Avastin 400 mg/16 ml (IV Infusion)
400 mg vial: ৳ 75,051.60
Medicine Details
| Category | Details |
|---|---|
| Generic | Bevacizumab |
| Company | Roche bangladesh ltd |
| Also available as |
Indications
- Metastatic colorectal cancer treatment with 5-fluorouracil-based chemotherapy
- Metastatic colorectal cancer treatment with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy
- Non-squamous non-small cell lung cancer treatment with carboplatin and paclitaxel
- Glioblastoma treatment as a single agent for progressive disease following prior therapy
- Metastatic renal cell carcinoma treatment with interferon alfa
- Cervical cancer treatment in combination with paclitaxel and cisplatin or paclitaxel and topotecan
- Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment in combination with various chemotherapy regimens
Pharmacology
- Recombinant humanized monoclonal IgG1 antibody
- Binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF)
- Produced in a mammalian cell expression system
- Clear to slightly opalescent, colorless to pale brown solution
Dosage
- Recommended doses for metastatic colorectal cancer
- Recommended doses for non-squamous non-small cell lung cancer
- Recommended dose for glioblastoma treatment
- Recommended dose for metastatic renal cell carcinoma treatment
- Recommended dose for cervical cancer treatment
- Recommended dose for platinum-resistant and platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Administration
- Not to be administered as IV push or bolus
- Preparation for administration using appropriate aseptic technique
- Initial infusion duration of 90 minutes
- Subsequent infusion duration based on tolerability
- Dilution in 0.9% Sodium Chloride injection, USP
- Visual inspection for particulate matter and discoloration prior to administration
Interaction
- No significant effect on the pharmacokinetics of irinotecan
Contraindications
- No contraindications listed in the manufacturer’s labeling
Side Effects
- Epistaxis
- Headache
- Hypertension
- Rhinitis
- Proteinuria
- Taste alteration
- Dry skin
- Rectal hemorrhage
- Lacrimation disorder
- Back pain
- Exfoliative dermatitis
Pregnancy & Lactation
- May cause fetal harm based on findings from animal studies
- Not recommended during breastfeeding
Precautions & Warnings
- Discontinue in case of perforation or fistula
- Discontinue for severe arterial thromboembolic events
- Discontinue for life-threatening venous thromboembolic events
- Monitor and treat hypertension
- Discontinue for posterior reversible encephalopathy syndrome
- Monitor urine protein and discontinue for nephrotic syndrome
- Stop for severe infusion reactions
- Advise on potential risks in pregnancy and the need for effective contraception
- Advise on the potential risk of ovarian failure
Use in Special Populations
- Not approved for use in patients under the age of 18 years
- Cases of non-mandibular osteonecrosis observed in patients under 18 years
- Severe adverse events in patients aged 65 years and above
Overdose Effects
- Associated with headache
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store in a refrigerator at 2-8°C
- Keep vial in the outer carton due to light sensitivity
- Do not freeze
- Keep out of reach of children